New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:12 EDTXOMAXOMA announces encouraging interim results from Gevokizumab Phase 2 study
XOMA announced preliminary top-line data from an interim analysis of its Phase 2 proof-of-concept, or POC, study to evaluate the safety and efficacy of gevokizumab, a potent modulator of interleukin-1 beta, for the treatment of the inflammatory facial lesions seen in patients with moderate to severe acne vulgaris. The Phase 2 POC study is a double-blind randomized comparison of gevokizumab 0.2mg/kg and 0.6mg/kg versus placebo given subcutaneously once per month for three consecutive months. Investigators have enrolled a total of approximately 125 patients to date, and the interim results are based on up to 92 patients with available data. In line with FDA guidance, inflammatory lesion counts, the primary endpoint in this trial, and overall acne severity as assessed by responder analysis of the Investigator Global Assessment, defined as at least a two-point improvement on a five-point scale, were measured at different time points up to Day 84.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
08:13 EDTXOMACapital Ventures reports 6.3% passive stake in XOMA
Subscribe for More Information
December 9, 2014
09:09 EDTXOMAXOMA raises $40M in a registered direct offering
XOMA (XOMA), announced today the pricing of 8,097,165 shares of its common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. Cowen and Company is acting as the sole placement agent.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use